JP Morgan Downgrades EverQuote to Neutral, Lowers Price Target to $17
JP Morgan analyst Cory Carpenter downgrades EverQuote (NASDAQ:EVER) from Overweight to Neutral and lowers the price target from $41 to $17.
Earnings Scheduled For November 1, 2021
Companies Reporting Before The Bell
• ANI Pharmaceuticals (NASDAQ:ANIP) is expected to report earnings for its third quarter.
Earnings Outlook For EverQuote
EverQuote (NASDAQ:EVER) is set to give its latest quarterly earnings report on Monday, 2021-11-01. Here's what investors need to know before the announcement.
Analysts estimate that EverQuote will likely report an Earnings Per Share (EPS) of $-0.16
Mid-Afternoon Market Update: Dow Surges Over 100 Points; Harmony Biosciences Shares Spike Higher
Toward the end of trading Tuesday, the Dow traded up 0.33% to 35,374.03 while the NASDAQ rose 0.54% to 15,103.67. The S&P also rose, gaining 0.55% to 4,511.35.
Mid-Day Market Update: Silver Surges 3%; Galera Therapeutics Shares Plunge
Midway through trading Tuesday, the Dow traded up 0.47% to 35,423.05 while the NASDAQ rose 0.59% to 15,110.79. The S&P also rose, gaining 0.61% to 4,513.69.
Why EverQuote Shares Are Falling
EverQuote Inc (NASDAQ: EVER) shares are trading lower by 17.7% at $14.27 after the company cut third-quarter sales guidance below estimates.
Needham Maintains Buy on EverQuote, Lowers Price Target to $19
Needham analyst Mayank Tandon maintains EverQuote (NASDAQ:EVER) with a Buy and lowers the price target from $45 to $19.